Technical Data
| Formula | C27H24F3N5O2 |
||||||||||||||
| Molecular Weight | 507.51 | CAS No. | 1818389-84-2 | ||||||||||||
| Solubility (25°C)* | In vitro | DMSO | 25 mg/mL (49.26 mM) | ||||||||||||
| Ethanol | 13 mg/mL (25.61 mM) | ||||||||||||||
| Water | Insoluble | ||||||||||||||
| In Vivo (Add solvents to the product individually and in order.) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||||||||||
Preparing Stock Solutions
Biological Activity
| Description | SPHINX31 is a SRPK1 inhibitor with an IC50 of 5.9 nM with high selectivity for SRPK1 over SRPK2 (50-fold) and CLK1 (100-fold). | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | Kinase assays showed that SPHINX31 is a type 1 kinase inhibitor (ATP competitive). This compound treatment results in inhibition of SRSF1 phosphorylation at 300 nM in PC3 prostate cancer cells. Metabolic stability in mouse liver microsomes shows that this chemical had medium clearance with a T1/2 of 95.79 min. Inhibition of SRPK1 using this inhibitor leads to cell cycle arrest and leukemic cell differentiation. |
||
| In Vivo | SPHINX31 could penetrate into the eye. This compound exerts a dose dependent inhibition of choroidal neovascularisation in mouse model. It inhibits blood vessel growth and macrophage infiltration. This chemical treatment prolongs survival of immunocompromised mice transplanted with MLL-rearranged AML cells. |
Protocol (from reference)
| Cell Assay: |
|
|---|---|
| Animal Study: |
|
References
|
Sellecks SPHINX31 Has Been Cited by 2 Publications
| Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia [ Leukemia, 2023, 37(8):1649-1659] | PubMed: 37422594 |
| SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection [ Antiviral Res, 2023, 10.1016/j.antiviral.2023.105756] | PubMed: 37992764 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.